{'fraction_non_alphanumeric': 0.023937267849773007, 'fraction_numerical': 0.007428807263722658, 'mean_word_length': 5.247422680412371, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
186 Deferoxamine Accelerates Hemorrhage Absorption for Patients With Traumatic Intracerebral Hematoma: A Prospective Randomized Controlled Trial.

INTRODUCTION
Traumatic brain injury (TBI) is a common disease for adults, particularly for young people. Most TBI patients have intracerebral hemorrhage, which often to brain edema and toxicity to the neural tissue. Deferoxamine (also known as Deferrioxamine B, Deferoxamine B, DFO-B, DFOA, DFB or desferal, DFX) is a bacterial siderophore produced by the Actinobacteria Streptomyces pilosus. It has medical applications as a chelating agent used to remove excess iron from the body. Animal models indicate that Deferoxamine accelerates intracranial hemorrhage absorption, although its effects on human patients remain unclear. In the present study, we investigated whether DFX can accelerate intracranial hemorrhage absorption, reduce acute hemorrhage-induced edema, and improve patient outcome.


METHODS
This is a prospective randomized controlled study. Eighty TBI patients with intracranial hemorrhage that does not require surgical evacuation were recruited. Patients were randomly assigned to group A or group B. Patients in group A were administered DFX 500 mg twice daily for 7 days, while those in group B received saline as control. The other therapies were conducted following the severe TBI guideline. The volume of hematomas and levels of brain edema were measured by magnetic resonance. Follow-up visits were conducted for each patient for 6 months by using Glasgow Outcome Score and Mini-Mental Status Examination as assessment tools.


RESULTS
The period of hemorrhage absorption (reduction of 50%) in group A was approximately 20% faster than in group B (P < .05). The significance of focal edema was also lower in group A. In the subgroup analysis, patients who had subdural hemorrhage and received DFX treatment required a 35.7% shorter time of hemorrhage absorption. The 6-month outcomes of patients with DFX treatment were also better than those in group B. No significant side effect was observed.


CONCLUSION
Based on our preliminary study, DFX offers faster hemorrhage absorption, less significant focal edema, and better outcome for patient with traumatic intracerebral hemorrhage. There is a reason to believe that DFX is effective and safe for traumatic Intracerebral hemorrhage treatment, yet further investigation with more patients is required.